Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Arcutis Biotherapeutics Executive Vice President and Chief Medical Officer Patrick Burnett reported an option exercise and share sale in Arcutis Biotherapeutics, Inc. common stock. On 12/15/2025, he exercised a stock option for 11,500 shares at an exercise price of $3.64 per share, then sold 11,500 shares on the same date at a weighted average price of $28.9436 per share under transaction code S.
These trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/12/2024, with a plan end date of 02/27/2026. After the transactions, Burnett beneficially owned 98,307 shares of common stock directly and 143,750 stock options. The report also corrects a prior overstatement of his beneficial ownership by 18 shares due to a scrivener's error.
Arcutis Biotherapeutics announced changes to its board leadership and a new consulting role for a retiring director. Bhaskar Chaudhuri retired from the board and as chair of the Compensation Committee on December 3, 2025, and entered into a transition and consulting agreement under which he will hold the honorary title of Founder and Director Emeritus and provide strategic advisory support through June 30, 2027. During this period, his existing stock options and restricted stock units will continue to vest, and he may exercise vested options, with a three-month post-termination exercise window.
On December 4, 2025, the board appointed Amit D. Munshi as a new Class II director and chair of the Compensation Committee, with a term running until the 2028 annual meeting of stockholders, subject to earlier departure events. As a non-employee director, he received an initial stock option grant for 16,502 shares of common stock and is eligible for a prorated annual equity award valued at approximately $300,000, allocated 65% to stock options and 35% to restricted stock units, plus prorated annual cash retainers of $50,000 for board service and $15,000 for chairing the Compensation Committee.
Arcutis Biotherapeutics (ARQT) director Sue-Jean Lin reported stock option exercises and a share sale. On 11/24/2025, Lin exercised options to acquire 18,052 shares of common stock at an exercise price of $8.63 per share and another 7,220 shares at $7.51 per share. That same day, Lin sold 25,272 shares of common stock at a weighted average price of $30.7833 per share, in multiple trades between $30.56 and $30.91. After these transactions, Lin directly beneficially owned 26,735 shares of Arcutis common stock, along with remaining stock options for 9,000 shares and 5,000 shares that are exercisable into common stock.
Arcutis Biotherapeutics (ARQT) insider Todd Franklin Watanabe, the company’s President, Chief Executive Officer and a director, reported open-market sales of common stock on a Form 4. On November 21, 2025, he sold 1,055 shares of common stock at a price of $30.00 per share. On November 24, 2025, he sold an additional 48,945 shares at a weighted average price of $30.3556 per share.
The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026. Following the reported sales, Watanabe beneficially owns 740,537 shares of Arcutis common stock directly, plus additional indirect holdings through several trusts and an LLC, for which he disclaims full beneficial ownership except to the extent of his economic interest.
Arcutis Biotherapeutics (ARQT) executive Masaru Matsuda, an officer serving as SVP General Counsel and Corporate Secretary, reported sales of company stock in a Form 4 filing. On 11/19/2025, he sold 989 shares of common stock at a weighted average price of $27.9541 and 1,561 shares at a weighted average price of $28.5. The sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units, rather than as discretionary open-market sales. After these transactions, Matsuda beneficially owned 151,476 shares of Arcutis common stock, held directly.
Arcutis Biotherapeutics (ARQT) director Halley E. Gilbert reported an option exercise and share sale. On 11/20/2025, Gilbert exercised a stock option to buy 12,220 shares of common stock at an exercise price of $7.51 per share. The underlying option had vested 100% on the first anniversary of May 31, 2023, subject to continuous service as a non-employee director.
On the same date, Gilbert sold 16,532 shares of common stock in open-market transactions at a weighted average price of $27.5491 per share, with individual trades ranging from $27.32 to $27.72. Following these transactions, Gilbert directly beneficially owned 22,123 shares of Arcutis Biotherapeutics common stock, and held no remaining derivative securities from this reported option.
Arcutis Biotherapeutics (ARQT) director Neha Krishnamohan reported option exercises and share sales. On 11/13/2025, she exercised stock options to acquire 27,052 shares at $8.63 and 12,220 shares at $7.51 per share, then sold 39,272 shares at a weighted average price of $23.1896 and an additional 1,232 shares at $23.37.
After these transactions, she directly owned 22,123 shares of Arcutis common stock. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, with an end date of November 2, 2026, which is designed to allow insiders to sell shares according to a preset schedule.
Arcutis Biotherapeutics, Inc. (ARQT) director Keith Leonard reported a charitable gift of company stock. On 11/13/2025, he transferred 4,312 shares of Arcutis common stock in a transaction coded as a gift at a stated price of $0, described as a transfer to a Charitable Remainder Unitrust. After this transaction, he reported owning 22,123 shares directly. He also reported 1,750 shares held indirectly through the Leonard Family Trust dated August 28, 1996, for which he serves as a trustee and disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics (ARQT): Reporting person Larry Todd Edwards, EVP Chief Commercial Officer, reported an open-market sale of 29,131 shares of common stock on 11/06/2025 at a weighted average price of $25.1597. The filing notes multiple trades within a $25.00–$25.2600 range.
Following the transaction, the reporting person beneficially owns 150,193 shares, held directly. The filer undertakes to provide detailed trade-by-trade information upon request, as customary for weighted-average disclosures.
Arcutis Biotherapeutics (ARQT) insider transaction: On 11/06/2025, the company’s Executive Vice President and Chief Medical Officer exercised stock options for 17,250 shares at $3.64 and sold 17,250 common shares at a weighted average price of $24.1823, with trades executed between $23.79 and $24.4493. The transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
Following these transactions, the reporting person beneficially owned 98,325 shares of common stock and 155,250 derivative securities (options). The reported option grant vests monthly over four years from January 12, 2024, until fully vested on the fourth anniversary.